Clinical Core - Pharmacogenomics of Statin Therapy (POST)

临床核心 - 他汀类药物治疗的药物基因组学 (POST)

基本信息

批准号：
9139484
负责人：
Carlos Iribarren
金额：
$ 50.87万
依托单位：
CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9139484
关键词：
Adopted Adult Adverse effects Aging Biomedical Research California Caring Cell model Clinical Clinical Research Cohort Studies Collection Computerized Medical Record Coronary DNA Data Data Set Diabetes Mellitus Disease Electronic Health Record Environment Epidemiologic Studies Event Exposure to Feces Future Genes Genotype Group Practice Guidelines Health Human In Vitro Individual Informatics Lipids Medical Medical Electronics Metabolic Molecular Myopathy Participant Patients Pharmacogenomics Pharmacologic Substance Pharmacy facility Plasma Population Population Heterogeneity Recording of previous events Records Recruitment Activity Research Resources Role Sampling Simvastatin Site Stroke Study Subject System Variant Whole Blood adverse outcome base biobank c new clinical practice cohort database query design ethnic diversity exome follow-up genetic analysis genetic epidemiology genetic information genome wide association study genome-wide health care delivery healthy aging lymphoblastoid cell line member phenotypic data programs prospective racial diversity response socioeconomics transcriptomics

项目摘要

CLINICAL CORE: PROJECT SUMMARY The Clinical Core at the Division of Research, Kaiser Permanente of Northern California (KPNC) is a key component of the overall POST Center. It serves a vital role by providing all the human participants for Project 1, and all the genotypic data, phenotypic data, and DNA samples to Project 3. The aims of the POST Clinical Core are: 1) To obtain whole blood and plasma from KPNC statin users with a) a major adverse coronary event (MACE, N=124) while on treatment, b) statin-induced myopathy (N=124), c) new onset diabetes (N=124), and d) three sets of 124 matched controls (N=372) for the studies in Project 1 (“Molecular Determinants of Statin Efficacy and Adverse Effects using Cellular Models”, Drs. Medina and Krauss); 2) With Project 3 (“Genome-wide Association Study of Statin Response and its Consequences”, Dr. Risch), create a dataset of medical and pharmacy information relevant to statin effects on lipids, MACE, stroke, statin-induced myopathy and new onset diabetes from the electronic medical records of patients in the GERA cohort; and 3) Provide DNA samples from selected statin users within the GERA cohort (n=2,517) and within the extended Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) biorepository (n=843) to Project 3 for follow-up genetic analysis of candidate loci identified throughout the Center's research program.

临床核心：项目摘要研究部的临床核心，北加州的Kaiser Permanente（KPNC）是关键整个邮政中心的组成部分。它通过为项目提供所有人类参与者来发挥至关重要的作用 1，以及所有基因型数据，表型数据和DNA样品，用于项目3。核心是：1）从KPNC他汀类药物使用者获得全血和血浆，a）主要逆境事件（狼牙棒，n = 124）在治疗时，b）他汀类药物诱导的肌病（n = 124），c）新发作糖尿病（n = 124），d）项目1研究的三组124个匹配的对照（n = 372）（“分子他汀类药物疗效和使用细胞模型的不良反应的决定因素”，麦地那博士和克劳斯; 2）项目3（“全基因组全基因组协会的汀类药物反应及其后果研究”，Risch博士），创建一个与他汀类药物对脂质，狼牙棒，中风，他汀类药物诱导有关的医学和药房信息数据集来自GERA队列患者的电子病历的肌病和新发作糖尿病； 3）提供来自GERA队列中选定的他汀类药物用户的DNA样品（n = 2,517），并在扩展中提供 Kaiser Permanente基因，环境与健康研究计划（RPGEH）生物座（n = 843）项目3用于对整个中心研究计划中确定的候选地点的后续遗传分析。